Digital Content 
NEWS #PharmaBuzz
14 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/14/3166085/18362/en/Amarin-and-HLS-Therapeutics-Collaborate-on-Presenting-REDUCE-IT-and-EPA-Mechanistic-Data-at-the-Canadian-Cardiovascular-Congress.html
25 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/25/3138380/18362/en/New-Analyses-from-REDUCE-IT-and-EPA-Mechanistic-Data-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress-2025.html
24 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/24/3104106/18362/en/Amarin-Announces-Exclusive-License-and-Supply-Agreement-with-Recordati-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Europe.html
18 Jun 2025
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-18-2025-14246.pdf
31 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/31/3052239/18362/en/Amarin-Highlights-Recent-Data-Presented-at-ACC-25-Evaluating-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-in-Lp-a-Enriched-Plasma-and-in-Combination-with-GLP-1-Agonist.html
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3033894/18362/en/Amarin-Marks-Key-Milestone-for-VASCEPA-VAZKEPA-Icosapent-Ethyl-Publication-of-Post-Hoc-Analysis-of-REDUCE-IT-in-Journal-of-the-American-Heart-Association-Reports-Benefit-on-Top-of-.html
Share 